1. Areas of Special Interest in PsO

2. Genital PsO: Patients' Perspectives

3. Long-Term Efficacy With IL-17 Inhibitor Ixekizumab: UNCOVER-1

4. Long-Term Efficacy With IL-23p19 Inhibitor Guselkumab: VOYAGE-1

5. Adverse Events Through Week 56 (ECLIPSE)

6. IL-17 and IL-23p19 Inhibitors Are Effective in Areas of Special Interest

7. Risankizumab Withdrawal and Persistence of PASI 90 Response: IMMhance

8. Guselkumab Withdrawal and Persistence of PASI 90 Response: VOYAGE-2

9. Safety Profile of Guselkumab and Risankizumab

10. Abbreviations